Tag: voriconazole

1. Posaconazole  was non-inferior to voriconazole with respect to all-cause mortality at day 42 (15% vs. 21%, respectively). 2. Incidence of treatment-related adverse events was lower for posaconazole than voriconazole.  Evidence Rating Level: 2 (Good)  Study Rundown: Invasive aspergillosis (IA) is a life-threatening infection that commonly occurs in patients with immunosuppression. Currently, voriconazole serves as...
1. Posaconazole  was non-inferior to voriconazole with respect to all-cause mortality at day 42 (15% vs. 21%, respectively). 2. Incidence of treatment-related adverse events was lower for posaconazole than voriconazole.  Evidence Rating Level: 2 (Good)  Study Rundown: Invasive aspergillosis (IA) is a life-threatening infection that commonly occurs in patients with immunosuppression. Currently,...
1. In immunocompromised patients with invasive aspergillosis, treatment with voriconazole was found to be superior to amphotericin B in achieving successful outcomes. 2. The incidence of serious adverse events was significantly lower in patients in the voriconazole group, as compared with those in the amphotericin B group. Original Date of Publication:...